Tetrabenazine as anti-chorea therapy in Huntington Disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators |
| |
Authors: | Samuel Frank |
| |
Institution: | (1) 72 East Concord St., C329 Boston, MA 02118, USA |
| |
Abstract: | Background Tetrabenazine (TBZ) selectively depletes central monoamines by reversibly binding to the type-2 vesicular monoamine transporter.
A previous double blind study in Huntington disease (HD) demonstrated that TBZ effectively suppressed chorea, with a favorable
short-term safety profile (Neurology 2006;66:366-372). The objective of this study was to assess the long-term safety and effectiveness of TBZ for chorea in HD. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|